Yang Y, Nadanaciva S, Will Y, Woodhead J L, Howell B A, Watkins P B, Siler S Q
Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA.
Pharm Res. 2015 Jun;32(6):1975-92. doi: 10.1007/s11095-014-1591-0. Epub 2014 Dec 12.
MITOsym, a new mathematical model of hepatocellular respiration and bioenergetics, has been developed in partnership with the DILIsym® model with the purpose of translating in vitro compound screening data into predictions of drug induced liver injury (DILI) risk for patients. The combined efforts of these two models should increase the efficiency of evaluating compounds in drug development in addition to enhancing patient care.
MITOsym includes the basic, essential biochemical pathways associated with hepatocellular respiration and bioenergetics, including mitochondrial oxidative phosphorylation, electron transport chain activity, mitochondrial membrane potential, and glycolysis; also included are dynamic feedback signals based on perturbation of these pathways. The quantitative relationships included in MITOsym are based primarily on published data; additional new experiments were also performed in HepG2 cells to determine the effects on oxygen consumption rate as media glucose concentrations or oligomycin concentrations were varied. The effects of varying concentrations of FCCP on the mitochondrial proton gradient were also measured in HepG2 cells.
MITOsym simulates and recapitulates the reported dynamic changes to hepatocellular oxygen consumption rates, extracellular acidification rates, the mitochondrial proton gradient, and ATP concentrations in the presence of classic mitochondrial toxins such as rotenone, FCCP, and oligomycin.
MITOsym can be used to simulate hepatocellular respiration and bioenergetics and provide mechanistic hypotheses to facilitate the translation of in vitro data collection to predictions of in vivo human hepatotoxicity risk for novel compounds.
MITOsym是一种新的肝细胞呼吸和生物能量学数学模型,它与DILIsym®模型合作开发,目的是将体外化合物筛选数据转化为对患者药物性肝损伤(DILI)风险的预测。这两个模型的共同努力除了改善患者护理外,还应提高药物开发中化合物评估的效率。
MITOsym包括与肝细胞呼吸和生物能量学相关的基本、必要生化途径,包括线粒体氧化磷酸化、电子传递链活性、线粒体膜电位和糖酵解;还包括基于这些途径扰动的动态反馈信号。MITOsym中包含的定量关系主要基于已发表的数据;还在HepG2细胞中进行了额外的新实验,以确定随着培养基葡萄糖浓度或寡霉素浓度变化对氧消耗率的影响。还在HepG2细胞中测量了不同浓度的FCCP对线粒体质子梯度的影响。
MITOsym模拟并概括了在存在鱼藤酮、FCCP和寡霉素等经典线粒体毒素的情况下,肝细胞氧消耗率、细胞外酸化率、线粒体质子梯度和ATP浓度的动态变化。
MITOsym可用于模拟肝细胞呼吸和生物能量学,并提供机制假设,以促进将体外数据收集转化为对新型化合物体内人类肝毒性风险的预测。